Model Detail Talk of

Launching Literature
 1st Page:
Dear Sir, in this visual you can see a post-menopausal woman is enjoying freedom in a swing
eradicating Recurrent VULVOVAGINAL CANDIDIASIS from her life, that indicates Permanent
FREEDOM from Recurrent VULVOVAGINAL CANDIDIASIS.
 2nd Page:
Recurrent Vulvovaginal Candidiasis (RVVC) affects nearly 138 million women globally each year.
Due to having age related immunosuppression and uncontrolled diabetes mellitus, post-
menopausal women are at high risk of chronic or recurrent vulvovaginal candidiasis.
Oteseconazole is US-FDA approved novel oral selective inhibitor of fungal demethylase enzyme
to treat Recurrent Vulvovaginal Candidiasis (RVVC) for post-menopausal patients.
Beximco Pharma for the 1st time in Bangladesh proudly introduces, US-FDA approved antifungal
to eradicate RVVC of postmenopausal patients, Vulcan, Oteseconazole 150 mg Capsule, that
Removes RVVC Permanently.
 3rd Page:
Sir, Vulcan (Oteseconazole) inhibits 14-alpha demethylase (CYP51) enzyme that catalyzes early
step of ergosterol biosynthesis which is required for fungal cell membrane formation and
integrity.
Inhibition of 14-alpha demethylase (CYP51) results breakdown of fungal cell membrane and kills
them. Through the inclusion of a tetrazole metal-binding group, Oteseconazole has a lower
affinity for human CYP enzymes.
Here is the pictorial representation of the mechanism of action of Vulcan. Vulcan kills Candida
causing fungus permanently.
 4th Page:
Sir, Oteseconazole (Vulcan) is more powerful than Fluconazole against azole resistant Candida
species,
Vulcan (Oteseconazole) is 64 times more powerful than Fluconazole against azole resistant
Candida albicans.
Vulcan (Oteseconazole) is also 32 times more powerful than Fluconazole against azole resistant
Candida glabarta. Ensures excellent treatment outcome.
 5th Page:
Vulcan (Oteseconazole) showed only 6.7% relapse rate of Recurrent Vulvo-vaginal Candidiasis
after 48 weeks of follow-up.
Relapse rate of RVVC of Vulcan (Oteseconazole) is only 6.7%. Whereas Relapse rate of RVVC of
Placebo is 42.8%. Ensures persistent solution of RVVC.
 6th Page:
Rx:
✓ Recurrent vulvovaginal candidiasis (RVVC) in females who are not of reproductive
potential.
✓ Vulcan® should only be taken by females who are not pregnant and who are not able to
become pregnant.
Dosage and Administration: (Vulcan Capsule is to be taken with food)
For Vulcan-only:
On Day 1: Administer Vulcan 600 mg (as a single dose), then,
On Day 2: Administer Vulcan 450 mg (as a single dose), then,
Beginning on Day 14: Administer Vulcan 150 mg once a week (every 7 days) for 11 weeks (Weeks
2 through 12).
With Fluconazole:
On Day 1, Day 4, and Day 7: Administer Fluconazole 150 mg orally, then
On Days 14 through 20: Administer Vulcan 150 mg once daily for 7 days, then
Beginning on Day 28: Administer Vulcan 150 mg once a week (every 7 days) for 11 weeks (Weeks
4 through 14).
Considering all the features, advantages, and benefits, may I expect your valuable prescription
support in favor of Vulcan® to eradicate RVVC of postmenopausal patients? In my next call, I shall
come to know about your feedback and experience regarding Vulcan®.